| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
63,980,000 |
| Market
Cap: |
610.37(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.22 - $11.59 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 18.6 |
| Insider 6 Months : 18.6 |
| Insider 3/6 Months : 37.7 |
|
| Guru Rank Number : 245 |
| Guru Rank Value : 4.8 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,499,124 |
1,499,124 |
1,499,124 |
1,499,124 |
| Total Buy Value |
$13,117,335 |
$13,117,335 |
$13,117,335 |
$13,117,335 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
1,254 |
5,114 |
22,963 |
172,089 |
| Total Sell Value |
$10,922 |
$50,468 |
$231,475 |
$1,835,193 |
| Total People Sold |
1 |
2 |
2 |
4 |
| Total Sell Transactions |
1 |
3 |
11 |
21 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Broshy Eran |
Director |
– • – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
12,000 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
280,000 |
882,056 |
|
- |
|
| Worboys Philip D |
SVP, Translational Science |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
105,000 |
179,943 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
115,000 |
251,165 |
|
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
105,000 |
168,561 |
|
- |
|
| Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
211,508 |
|
- |
|
| Mammen Mathai |
SVP, Research & Development |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
288,111 |
|
- |
|
| Pasqualone Frank |
Sr. VP, Operations |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
217,178 |
|
- |
|
| Hegde Sharathchandra S |
SVP, Research |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
105,000 |
177,165 |
|
- |
|
| Gala Renee D |
SVP, Chief Financial Officer |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
238,125 |
|
- |
|
| Lee Junning |
Sr. VP, Technical Operations |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
244,335 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2016-03-14 |
4 |
B |
$23,028,000.00 |
$2,147,483,647 |
I/I |
1,301,015 |
9,644,807 |
1.5 |
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm PlngOff |
• – – |
2016-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
63,561 |
|
- |
|
| Hegde Sharathchandra S |
SVP, ResearchOfficer |
• – – |
2016-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
72,165 |
|
- |
|
| Worboys Philip D |
SVP, Translational ScienceOffi |
• – – |
2016-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
74,943 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2016-02-20 |
4 |
D |
$15.65 |
$251,981 |
D/D |
(16,101) |
182,731 |
|
- |
|
| Gala Renee D |
SVP, Chief Financial Officer |
• – – |
2016-02-20 |
4 |
D |
$15.65 |
$204,264 |
D/D |
(13,052) |
148,125 |
|
- |
|
| Lee Junning |
Sr. VP, Technical Operations |
• – – |
2016-02-20 |
4 |
D |
$15.65 |
$251,167 |
D/D |
(16,049) |
154,335 |
|
- |
|
| Haumann Brett K |
SVP, Clinical Development |
• – – |
2016-02-20 |
4 |
D |
$15.65 |
$288,351 |
D/D |
(18,425) |
121,508 |
|
- |
|
| Pasqualone Frank |
Sr. VP, Operations |
• – – |
2016-02-20 |
4 |
D |
$15.65 |
$169,490 |
D/D |
(10,830) |
127,178 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2016-02-20 |
4 |
D |
$15.65 |
$296,098 |
D/D |
(18,920) |
136,165 |
|
- |
|
| Mammen Mathai |
SVP, Research & Development |
• – – |
2016-02-20 |
4 |
D |
$15.65 |
$310,559 |
D/D |
(19,844) |
198,111 |
|
- |
|
| Lee Junning |
Sr. VP, Technical Operations |
• – – |
2015-11-20 |
4 |
D |
$17.17 |
$17,805 |
D/D |
(1,037) |
170,384 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2015-11-20 |
4 |
D |
$17.17 |
$16,037 |
D/D |
(934) |
155,085 |
|
- |
|
| Haumann Brett K |
SVP, Clinical Development |
• – – |
2015-11-20 |
4 |
D |
$17.17 |
$13,410 |
D/D |
(781) |
139,933 |
|
- |
|
530 Records found
|
|
Page 19 of 22 |
|
|
0.06 (0.63%) 
